Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

198.52
-0.5000-0.25%
Post-market: 197.31-1.2150-0.61%16:38 EDT
Volume:503.55K
Turnover:100.08M
Market Cap:10.40B
PE:-52.68
High:200.74
Open:199.00
Low:197.05
Close:199.02
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:1.04
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:124.83
PE(LYR):-53.91

Loading ...

Axsome Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Apr 11

Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says

MT Newswires Live
·
Apr 10

UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating

MT Newswires Live
·
Apr 10

Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
Apr 09

Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating

TIPRANKS
·
Apr 09

Axsome Therapeutics to report first-quarter results, host conference call

Reuters
·
Apr 08

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

GlobeNewswire
·
Apr 08

RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

Reuters
·
Apr 01

Axsome buys global rights to Takeda schizophrenia drug candidate balipodect (TAK-063)

Reuters
·
Apr 01

Axsome Therapeutics Inc - to Begin Phase 3 Trial-Enabling Activities for Schizophrenia in 2026

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Inc - Obtains Exclusive Global Rights to Balipodect From Takeda

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Inc - Takeda Receives Upfront Payment, Eligible for Milestone Payments and Royalties

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

GlobeNewswire
·
Apr 01

Axsome Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 25

Axsome Therapeutics price target raised to $245 from $220 at Guggenheim

TIPRANKS
·
Mar 25

Axsome Still Offers 'Compelling' Core Story, RBC Says

MT Newswires Live
·
Mar 14

RBC Capital Remains a Buy on Axsome Therapeutics (AXSM)

TIPRANKS
·
Mar 13